Professor Chan Cheah Discusses Early Results for Phase I LOXO-305 (BRUIN) Trial at the 62nd American Society of Haematology Annual Meeting and Exposition 2020.

Bruton’s Tyrosine Kinase (BTK) inhibitors have become an important part of treatment in patients with Chronic Lymphocytic Leukaemia and B-Cell Lymphomas including Mantle Cell Lymphoma and Waldenstrom’s Macroglobulineamia.

Professor Chan Cheah discusses early results of the large phase I LOXO-305 (BRUIN) trial which evaluates a non-covalent reversible BTK inhibitor LOXO-305 in patients with previously treated B-cell malignancies. Overall, LOXO-305 has a good safety profile with few severe adverse events and a favourable side-effect profile relative to first generation BTK inhibitors. Furthermore, activity was observed across a range of b-cell malignancies where BTK inhibition was expected to be successful including amongst patients who experienced treatment failure due to intolerance and resistance to first generation BTK inhibitors.